{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:18:36Z","timestamp":1794129516581,"version":"4.8.0"},"reference-count":30,"publisher":"Innovative Healthcare Institute","issue":"2","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Introduction: Colitis is one of the most common immune-related adverse events in patients receiving immune checkpoint inhibitors. Although radiographic changes on computed tomography (CT), such as mild diffuse bowel thickening, mesenteric fat stranding, and mucosal enhancement, have been reported, the utility of CT in diagnosis of patients with suspected immune-related colitis is not well documented. The aim of this retrospective study was to determine the value of CT scans in diagnosis of immunotherapy-induced colitis.<\/jats:p>\n                  <jats:p>Methods: CT scans of the abdomen and pelvis of 34 patients receiving immunotherapy who had a clinical diagnosis of immunotherapy-induced colitis and 19 patients receiving immunotherapy without clinical symptoms of colitis (controls) were evaluated. Segments of the colon (rectum, sigmoid, descending, transverse, ascending, and cecum) were assessed independently by two abdominal imaging specialists, blinded to the clinical diagnosis. Each segment was assessed for radiographic signs such as mucosal enhancement, wall thickening, distension, and periserosal fat stranding. The presence of any of the signs was considered radiographic evidence of colitis.<\/jats:p>\n                  <jats:p>Results: CT findings suggestive of colitis was seen in 20 of 34 patients with symptoms of colitis and in 5 of 19 patients without symptoms of colitis. The sensitivity, specificity, positive predictive value, and negative predictive value for colitis on CT were 58.8%, 73.7%, 80%, and 50%, respectively.<\/jats:p>\n                  <jats:p>Conclusions: We found that CT had a low sensitivity, specificity, and negative predictive value for the diagnosis of immunotherapy-induced colitis. We therefore conclude that CT has a limited role in the diagnosis of patients with suspected uncomplicated immune-related colitis.<\/jats:p>","DOI":"10.36401\/jipo-21-21","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T13:30:47Z","timestamp":1652967047000},"page":"32-36","source":"Crossref","is-referenced-by-count":10,"title":["Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis"],"prefix":"10.36401","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-7552","authenticated-orcid":true,"given":"Juan","family":"Ibarra Rovira","sequence":"first","affiliation":[{"name":"Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvi","family":"Thirumurthi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Taggart","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Lee","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye Lynette","family":"Ejezie","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fechukwu O.","family":"Akhmedzhanov","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrazzak","family":"Zarifa","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Hong","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-7934","authenticated-orcid":true,"given":"Raghunandan","family":"Vikram","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"2022051917272935900_i2590-017X-5-2-32-b01","doi-asserted-by":"crossref","unstructured":"Michot\n              JM,\n            \n            \n              Bigenwald\n              C,\n            \n            \n              Champiat\n              S,\n            \n            et al.\n          \n          Immune-related adverse events with immune checkpoint blockade: a comprehensive review.\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2016;\n\t\t\t\t\t54:\n\t\t\t\t\t139\u2013\n\t\t\t\t\t148.","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2022051917272935900_i2590-017X-5-2-32-b02","doi-asserted-by":"crossref","unstructured":"Brahmer\n              JR,\n            \n            \n              Lacchetti\n              C,\n            \n            \n              Schneider\n              BJ,\n            \n            et al.\n          \n          Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t36:\n\t\t\t\t\t1714\u2013\n\t\t\t\t\t1768.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2022051917272935900_i2590-017X-5-2-32-b03","doi-asserted-by":"crossref","unstructured":"Naing\n              A,\n            \n            \n              Hajjar\n              J,\n            \n            \n              Gulley\n              JL,\n            \n            et al.\n          \n          Strategies for improving the management of immune-related adverse events. J Immunother Cancer.\n          2020;\n\t\t\t\t\t8. DOI: 10.1136\/jitc-2020-001754","DOI":"10.1136\/jitc-2020-001754"},{"key":"2022051917272935900_i2590-017X-5-2-32-b04","doi-asserted-by":"crossref","unstructured":"Ramos-Casals\n              M,\n            \n            \n              Brahmer\n              JR,\n            \n            \n              Callahan\n              MK,\n            \n            et al.\n          \n          Immune-related adverse events of checkpoint inhibitors.\n\t\t\t\t\tNat Rev Dis Primers.\n\t\t\t\t\t2020;\n\t\t\t\t\t6:\n\t\t\t\t\t38.","DOI":"10.1038\/s41572-020-0160-6"},{"key":"2022051917272935900_i2590-017X-5-2-32-b05","doi-asserted-by":"crossref","unstructured":"Marin-Acevedo\n              JA,\n            \n            \n              Harris\n              DM,\n            \n            \n              Burton\n              MC.\n            \n          \n          Immunotherapy-induced colitis: an emerging problem for the hospitalist.\n\t\t\t\t\tJ Hosp Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t13:\n\t\t\t\t\t413\u2013\n\t\t\t\t\t418.","DOI":"10.12788\/jhm.2925"},{"key":"2022051917272935900_i2590-017X-5-2-32-b06","doi-asserted-by":"crossref","unstructured":"Marthey\n              L,\n            \n            \n              Mateus\n              C,\n            \n            \n              Mussini\n              C,\n            \n            et al.\n          \n          Cancer Immunotherapy with Anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease.\n\t\t\t\t\tJ Crohns Colitis.\n\t\t\t\t\t2016;\n\t\t\t\t\t10:\n\t\t\t\t\t395\u2013\n\t\t\t\t\t401.","DOI":"10.1093\/ecco-jcc\/jjv227"},{"key":"2022051917272935900_i2590-017X-5-2-32-b07","doi-asserted-by":"crossref","unstructured":"Gupta\n              A,\n            \n            \n              De Felice\n              KM,\n            \n            \n              Loftus\n              EV,\n              Jr.,\n            \n            \n              Khanna\n              S.\n            \n          \n          Systematic review: colitis associated with anti-CTLA-4 therapy.\n\t\t\t\t\tAliment Pharmacol Ther.\n\t\t\t\t\t2015;\n\t\t\t\t\t42:\n\t\t\t\t\t406\u2013\n\t\t\t\t\t417.","DOI":"10.1111\/apt.13281"},{"key":"2022051917272935900_i2590-017X-5-2-32-b08","doi-asserted-by":"crossref","unstructured":"Beck\n              KE,\n            \n            \n              Blansfield\n              JA,\n            \n            \n              Tran\n              KQ,\n            \n            et al.\n          \n          Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2006;\n\t\t\t\t\t24:\n\t\t\t\t\t2283\u2013\n\t\t\t\t\t2289.","DOI":"10.1200\/JCO.2005.04.5716"},{"key":"2022051917272935900_i2590-017X-5-2-32-b09","doi-asserted-by":"crossref","unstructured":"Howell\n              M,\n            \n            \n              Lee\n              R,\n            \n            \n              Bowyer\n              S,\n            \n            et al.\n          \n          Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.\n\t\t\t\t\tLung Cancer.\n\t\t\t\t\t2015;\n\t\t\t\t\t88:\n\t\t\t\t\t117\u2013\n\t\t\t\t\t123.","DOI":"10.1016\/j.lungcan.2015.02.007"},{"key":"2022051917272935900_i2590-017X-5-2-32-b10","doi-asserted-by":"crossref","unstructured":"Weber\n              JS,\n            \n            \n              Kahler\n              KC,\n            \n            \n              Hauschild\n              A.\n            \n          \n          Management of immune-related adverse events and kinetics of response with ipilimumab.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2012;\n\t\t\t\t\t30:\n\t\t\t\t\t2691\u2013\n\t\t\t\t\t2697.","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2022051917272935900_i2590-017X-5-2-32-b11","doi-asserted-by":"crossref","unstructured":"Weber\n              J.\n            \n          \n          Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.\n\t\t\t\t\tOncologist.\n\t\t\t\t\t2007;\n\t\t\t\t\t12:\n\t\t\t\t\t864\u2013\n\t\t\t\t\t872.","DOI":"10.1634\/theoncologist.12-7-864"},{"key":"2022051917272935900_i2590-017X-5-2-32-b12","doi-asserted-by":"crossref","unstructured":"Lord\n              JD,\n            \n            \n              Hackman\n              RC,\n            \n            \n              Moklebust\n              A,\n            \n            et al.\n          \n          Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.\n\t\t\t\t\tDig Dis Sci.\n\t\t\t\t\t2010;\n\t\t\t\t\t55:\n\t\t\t\t\t1396\u2013\n\t\t\t\t\t1405.","DOI":"10.1007\/s10620-009-0839-8"},{"key":"2022051917272935900_i2590-017X-5-2-32-b13","unstructured":"National Cancer Institute, National Institutes of Health.\n          Common Terminology Criteria for Adverse Events (CTCAE) version 5. US Department of Health and Human Services, NIH, NCI;\n          2017."},{"key":"2022051917272935900_i2590-017X-5-2-32-b14","doi-asserted-by":"crossref","unstructured":"Freites-Martinez\n              A,\n            \n            \n              Santana\n              N,\n            \n            \n              Arias-Santiago\n              S,\n            \n            \n              Viera\n              A.\n            \n          \n          Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of side effects of antineoplastic treatments.\n\t\t\t\t\tActas Dermosifiliogr.\n\t\t\t\t\t2021;\n\t\t\t\t\t112:\n\t\t\t\t\t90\u2013\n\t\t\t\t\t92.","DOI":"10.1016\/j.adengl.2019.05.021"},{"key":"2022051917272935900_i2590-017X-5-2-32-b15","doi-asserted-by":"crossref","unstructured":"Abu-Sbeih\n              H,\n            \n            \n              Ali\n              FS,\n            \n            \n              Luo\n              W,\n            \n            et al.\n          \n          Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.\n\t\t\t\t\tJ Immunother Cancer.\n\t\t\t\t\t2018;\n\t\t\t\t\t6:\n\t\t\t\t\t95.","DOI":"10.1186\/s40425-018-0411-1"},{"key":"2022051917272935900_i2590-017X-5-2-32-b16","doi-asserted-by":"crossref","unstructured":"Puzanov\n              I,\n            \n            \n              Diab\n              A,\n            \n            \n              Abdallah\n              K,\n            \n            et al.\n          \n          Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.\n\t\t\t\t\tJ Immunother Cancer.\n\t\t\t\t\t2017;\n\t\t\t\t\t5:\n\t\t\t\t\t95.","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2022051917272935900_i2590-017X-5-2-32-b17","doi-asserted-by":"crossref","unstructured":"Tirumani\n              SH,\n            \n            \n              Ramaiya\n              NH,\n            \n            \n              Keraliya\n              A,\n            \n            et al.\n          \n          Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab.\n\t\t\t\t\tCancer Immunol Res.\n\t\t\t\t\t2015;\n\t\t\t\t\t3:\n\t\t\t\t\t1185\u2013\n\t\t\t\t\t1192.","DOI":"10.1158\/2326-6066.CIR-15-0102"},{"key":"2022051917272935900_i2590-017X-5-2-32-b18","doi-asserted-by":"crossref","unstructured":"Kim\n              KW,\n            \n            \n              Ramaiya\n              NH,\n            \n            \n              Krajewski\n              KM,\n            \n            et al.\n          \n          Ipilimumab-associated colitis: CT findings.\n\t\t\t\t\tAJR Am J Roentgenol.\n\t\t\t\t\t2013;\n\t\t\t\t\t200:\n\t\t\t\t\tW468\u2013\n\t\t\t\t\tW474.","DOI":"10.2214\/AJR.12.9751"},{"key":"2022051917272935900_i2590-017X-5-2-32-b19","doi-asserted-by":"crossref","unstructured":"Park\n              H,\n            \n            \n              Hatabu\n              H,\n            \n            \n              Ricciuti\n              B,\n            \n            et al.\n          \n          Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.\n\t\t\t\t\tEur J Radiol.\n\t\t\t\t\t2020;\n\t\t\t\t\t132:\n\t\t\t\t\t109275.","DOI":"10.1016\/j.ejrad.2020.109275"},{"key":"2022051917272935900_i2590-017X-5-2-32-b20","doi-asserted-by":"crossref","unstructured":"Bronstein\n              Y,\n            \n            \n              Ng\n              CS,\n            \n            \n              Hwu\n              P,\n            \n            \n              Hwu\n              WJ.\n            \n          \n          Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.\n\t\t\t\t\tAJR Am J Roentgenol.\n\t\t\t\t\t2011;\n\t\t\t\t\t197:\n\t\t\t\t\tW992\u2013\n\t\t\t\t\tW1000.","DOI":"10.2214\/AJR.10.6198"},{"key":"2022051917272935900_i2590-017X-5-2-32-b21","doi-asserted-by":"crossref","unstructured":"Wang\n              Y,\n            \n            \n              Abu-Sbeih\n              H,\n            \n            \n              Mao\n              E,\n            \n            et al.\n          \n          Endoscopic and histologic features of immune checkpoint inhibitor-related colitis.\n\t\t\t\t\tInflamm Bowel Dis.\n\t\t\t\t\t2018;\n\t\t\t\t\t24:\n\t\t\t\t\t1695\u2013\n\t\t\t\t\t1705.","DOI":"10.1093\/ibd\/izy104"},{"key":"2022051917272935900_i2590-017X-5-2-32-b22","doi-asserted-by":"crossref","unstructured":"Durbin\n              SM,\n            \n            \n              Mooradian\n              MJ,\n            \n            \n              Fintelmann\n              FJ,\n            \n            et al.\n          \n          Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer.\n          2020;\n\t\t\t\t\t8.DOI: 10.1136\/ jitc-2020-001329","DOI":"10.1136\/jitc-2020-001329"},{"key":"2022051917272935900_i2590-017X-5-2-32-b23","unstructured":"Krousel-Wood\n              MA,\n            \n            \n              Chambers\n              RB,\n            \n            \n              Muntner\n              P.\n            \n          \n          Clinicians' guide to statistics for medical practice and research: part I.\n\t\t\t\t\tOchsner J.\n\t\t\t\t\t2006;\n\t\t\t\t\t6:\n\t\t\t\t\t68\u2013\n\t\t\t\t\t83."},{"key":"2022051917272935900_i2590-017X-5-2-32-b24","doi-asserted-by":"crossref","unstructured":"Mercaldo\n              ND,\n            \n            \n              Lau\n              KF,\n            \n            \n              Zhou\n              XH.\n            \n          \n          Confidence intervals for predictive values with an emphasis to case-control studies.\n\t\t\t\t\tStat Med.\n\t\t\t\t\t2007;\n\t\t\t\t\t26:\n\t\t\t\t\t2170\u2013\n\t\t\t\t\t2183.","DOI":"10.1002\/sim.2677"},{"key":"2022051917272935900_i2590-017X-5-2-32-b25","unstructured":"Schaarschmidt\n              F.\n            \n          \n          bdpv: Inference and design for predictive values in diagnostic tests. R package version 1.3. 2019. Accessed Mar 18, 2022.\n          \n            cran.r-project.org\/package=bdpv"},{"key":"2022051917272935900_i2590-017X-5-2-32-b26","doi-asserted-by":"crossref","unstructured":"De Velasco\n              G,\n            \n            \n              Je\n              Y,\n            \n            \n              Bosse\n              D,\n            \n            et al.\n          \n          Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients.\n\t\t\t\t\tCancer Immunol Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t5:\n\t\t\t\t\t312\u2013\n\t\t\t\t\t318.","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"2022051917272935900_i2590-017X-5-2-32-b27","doi-asserted-by":"crossref","unstructured":"Thompson\n              JA,\n            \n            \n              Schneider\n              BJ,\n            \n            \n              Brahmer\n              J,\n            \n            et al.\n          \n          Management of immunotherapy-related toxicities, Version 1.2019.\n\t\t\t\t\tJ Natl Compr Canc Netw.\n\t\t\t\t\t2019;\n\t\t\t\t\t17:\n\t\t\t\t\t255\u2013\n\t\t\t\t\t289.","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2022051917272935900_i2590-017X-5-2-32-b28","doi-asserted-by":"crossref","unstructured":"De Velasco\n              G,\n            \n            \n              Je\n              YJ,\n            \n            \n              Bosse\n              D,\n            \n            et al.\n          \n          Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients.\n\t\t\t\t\tCancer Immunol Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t5:\n\t\t\t\t\t312\u2013\n\t\t\t\t\t318.","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"2022051917272935900_i2590-017X-5-2-32-b29","doi-asserted-by":"crossref","unstructured":"Wang\n              DY,\n            \n            \n              Salem\n              JE,\n            \n            \n              Cohen\n              JV,\n            \n            et al.\n          \n          Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.\n\t\t\t\t\tJAMA Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t4:\n\t\t\t\t\t1721\u2013\n\t\t\t\t\t1728.","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"2022051917272935900_i2590-017X-5-2-32-b30","doi-asserted-by":"crossref","unstructured":"Power\n              M,\n            \n            \n              Fell\n              G,\n            \n            \n              Wright\n              M.\n            \n          \n          Principles for high-quality, high-value testing.\n\t\t\t\t\tEvid Based Med.\n\t\t\t\t\t2013;\n\t\t\t\t\t18:\n\t\t\t\t\t5\u2013\n\t\t\t\t\t10.","DOI":"10.1136\/eb-2012-100645"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/5\/2\/32\/3060636\/i2590-017x-5-2-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/5\/2\/32\/3060636\/i2590-017x-5-2-32.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:36Z","timestamp":1765475316000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/5\/2\/article-p32.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5,19]]},"published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-21-21","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}